The HER2CLIMB study recently reported that the addition of tucatinib to trastuzumab and capecitabine improved both PFS and OS in heavily pretreated patients with HER2-positive breast cancer, including those with CNS metastases [26]. The gene discussed is ERBB2; the disease is breast carcinoma.